维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

6篇 您的检索式：作者名="Ryan Alexy"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	Towards high-throughput identification of endocrine disrupting compounds with mass spectrometry显示文摘	Cédric Bovet Benoit Plet Marc Ruff Sylvia Eiler Florence Granger Andreas Panagiotidis Ryan Wenzel Alexis Nazabal Dino Moras Renato Zenobi	2009	Toxicology in Vitro2009，，4：	2
	2	Vertebrate phylogeny of hydrogen sulfide vasoactivity显示文摘	Ryan AD Michael JR Alexis AS	2005	Am J Physiol Regul Integr Comp Physiol2005，288，1：	1
	3	Renal outcomes and mortality following hydroxyethyl starch resuscitation of critically ill patients: systematic review and meta-analysis of randomized trials 显示文摘	Ryan Z Alexis F T Dean A F	2009	Open Medicine2009，3，4：	1
	4	Changing Sexually Transmitted Infection Screening Protocol Will Result in Improved Case Finding for Trichomonas vaginalis Among High-Risk Female Populations显示文摘	Alexis M. Roth James A. Williams Ryan Ly Karen Curd Dan Brooks Janet Arno Barbara Van Der Pol	2011	Sexually Transmitted Diseases2011，，5：	1
	5	Single nucleotide polymorphism upstream of interleukin 28B associated with phase 1 and phase 2 of early viral kinetics in patients infected with HCV genotype 1显示文摘	Charles D. Howell Alexis Gorden Kathleen A. Ryan Alexander J. Thompson Chadi Ibrahim Michael Fried Nezam H. Afdhal John G. McHutchison Kevin V. Shianna David B. Goldstein Alan R. Shuldiner Braxton D. Mitchell	2012	Journal of Hepatology2012，，3：	1
	6	Multi-Institutional US Experience of the Occlutech AFR Device in Congenital and Acquired Heart Disease显示文摘Objectives:To detail the US multi-institutional experience with the Occlutech©(Occlutech International AB,Helsingborg,Sweden)atrial flow regulator(AFR)in children and adults with acquired or congenital heart disease.Background:The creation of a long-term atrial communication is desirable in several cardiovascular disease phenotypes,most notably pulmonary arterial hypertension,disorders of increased left ventricular filling and increased cavopulmonary pressures in patients with a Fontan type circulation.Methods:Patients were identified for inclusion from the AFR device manufacturer database.Data was collected using a RedCap database following IRB approval.8 weeks of follow up data was sought for each patient based on available data.Data was analyzed and summarized using SPSS.Results:We report the experience of 6 US centers in the implantation of AFR devices in 15 patients,across a wide age range,with different disease phenotypes and a variety of indications.Implantation was technically successful in all patients and improvement was noted in both clinical and hemodynamic parameters.There were no immediate or intermediate term complications reported.3 patients died remote from implantation.Their deaths were not felt to be related to the AFR device or related procedural complications.Conclusion:Compassionate use of the AFR device in children and adults with congenital&acquired heart disease is technically feasible and produces beneficial short term hemodynamic and symptomatic improvement.Widespread uptake of this technique and treatment at specialist centers has the potential to provide significant benefits to a variety of complex patients with currently limited treatment options and indeterminate prognosis.	Barry O’Callaghan Jenny Zablah Joseph Vettukattil Daniel Levi Morris Salem Allison Cabalka Jason Anderson Makram Ebeid Ryan Alexy Gareth J.Morgan	2022	Congenital Heart Disease2022，17，1：	1

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费